Accordingly, elucidation of the interplay between LRRK2 and PD-associated proteins α-synuclein and tau is highly relevant to the application of LRRK2-targeted therapeutics in suppressing PD-associated neuropathology. This evidence concerns the gene MAPT and Parkinson disease.